Roche reports good news in breast cancer combo trial
Roche announced that a Phase III trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
First Phase III immunotherapy study to demonstrate a statistically significant progression-free survival (PFS) improvement in intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) populations Encouraging ... Biopharmaceuticals, Oncology Genentech, Roche Group, TECENTRIQ, atezolizumab, triple negative, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 2, 2018 Category: Pharmaceuticals Source Type: news

Abraxane (Albumin-bound Paclitaxel for Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news

Roche 'highly encouraged' by Tecentriq results in breast cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Media News)
Source: Roche Media News - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - May 29, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - May 29, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 20, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - March 20, 2018 Category: Pharmaceuticals Source Type: news

Billionaire Patrick Soon-Shiong, who just purchased the Los Angeles Times, is a controversial figure in medicine
Patrick Soon-Shiong, a respected transplant surgeon from the University of California at Los Angeles turned entrepreneur and philanthropist, first became famous for inventing an important cancer drug. His idea involved packaging a tumor-poisoning substance inside the protein albumin, which is one of the main “foods” for cancer growth. The medication, Abraxane, is now used for a wide range […]Related:Robin Williams’s suicide was followed by a sharp rise in ‘copycat’ deathsFDA ramps up warnings about kratom, calling unregulated herb an ‘opioid’Why car horns, pla...
Source: Washington Post: To Your Health - February 7, 2018 Category: Consumer Health News Source Type: news

NICE recommends Celgene ’s pancreatic cancer treatment abraxane for NHS use
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Celgene ’s nab-paclitaxel as a life-extending treatment for patients with progressive pancreatic cancer that has progressed. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Were NHS chiefs right to deny pancreatic cancer drug?
The news in late 2015 that abraxane was being rejected by NICE on cost grounds was met with anger by patient groups as some people had survived years when they had been given months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2017 Category: Consumer Health News Source Type: news

Halozyme Therapeutics reports positive top-line results from HALO 202 study of PEGPH20
US-based biotechnology company Halozyme Therapeutics has reported positive topline results from a combined analysis of two stages of its Phase II HALO 202 study of PEGPH20 in combination with abraxane and gemcitabine to treat pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - January 6, 2017 Category: Pharmaceuticals Source Type: news

Glenmark, Particle Sciences to develop generic cancer drug
The partnership will develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 19, 2016 Category: Pharmaceuticals Source Type: news

Allergan Confirms Generic Abraxane(R) Patent Challenge
DUBLIN, March 17, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) ... Biopharmaceuticals, Generics, FDAAllergan, Abraxane, Paclitaxel (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2016 Category: Pharmaceuticals Source Type: news

Halozyme begins dosing in Phase III trial of PEGPH20 combination to treat pancreatic cancer
US-based Halozyme Therapeutics has begun a Phase III clinical trial (Halo-301) of its investigational drug, PEGPH20, in combination with Abraxane (nab-paclitaxel) and gemcitabine for previously untreated metastatic pancreatic cancer patients. (Source: Drug Development Technology)
Source: Drug Development Technology - March 17, 2016 Category: Pharmaceuticals Source Type: news

NICE approves idelalisib and tolvaptan, not Abraxane
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2015 Category: Drugs & Pharmacology Source Type: news

Bothell biotech OncoGenex stock drops after failed pancreatic cancer trial
The negative results of a pancreatic cancer clinical trial released this morning had a chilling effect on one Puget Sound-area biotech company's stock. Bothell-based OncoGenex Pharmaceuticals (Nasdaq: OGXI) this morning reported that a combination drug therapy did not succeed at treating pancreatic cancer in a Phase 2 clinical trial. In the trial, the company combined OncoGenex's drug apatorsen with Celgene's drug Abraxane and a chemotherapy drug called gemcitabine (two drugs that are already approved… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 23, 2015 Category: Biotechnology Authors: Annie Zak Source Type: news

Pancreatic cancer patients denied life-extending drug by spending watchdog
The health spending watchdog has refused to fund the pancreatic abraxane despite evidence that it can double life expectancy (Source: Telegraph Health)
Source: Telegraph Health - September 16, 2015 Category: Consumer Health News Tags: pancreatic cancer pancreas symptims nice drugs treatments funding decision Source Type: news

Molecular tinkering doubles cancer drug's efficacy
(Duke University) Researchers at Duke University have molecularly repackaged a widely used cancer drug called paclitaxel, more than doubling its effectiveness at destroying tumors than the current gold-standard pharmaceutical, Abraxane. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2015 Category: Global & Universal Source Type: news

Nanotechnology platform shows promise for treating pancreatic cancer
Scientists at UCLA’s California NanoSystems Institute and Jonsson Comprehensive Cancer Center have combined their nanotechnology expertise to create a new treatment that may solve some of the problems of using chemotherapy to treat pancreatic cancer. The study, published online in the journal ACS Nano, describes successful experiments to combine two drugs within a specially designed mesoporous silica nanoparticle that looks like a glass bubble. The drugs work together to shrink human pancreas tumors in mice as successfully as the current standard treatment, but at one twelfth the dosage. This lower dosage could ...
Source: UCLA Newsroom: Health Sciences - March 23, 2015 Category: Universities & Medical Training Source Type: news

Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
HONG KONG, March 18, 2015 -- (Healthcare Sales & Marketing Network) -- Celgene announced today that a new treatment option for late-stage pancreatic cancer is now available for use in Hong Kong. Approved by the Department of Health, Abraxane® (paclita... Biopharmaceuticals, Oncology, RegulatoryCelgene, Abraxane, paclitaxel, pancreatic cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2015 Category: Pharmaceuticals Source Type: news

EC grants approval for Celgene’s Abraxane to treat NSCLC
The European Commission (EC) has granted approval for Celgene International Sàrl's Abraxane (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin as a first-line treatment of non-small cell lung can… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 4, 2015 Category: Pharmaceuticals Source Type: news

Patients won't get vital pancreatic cancer drug that can extend life on the NHS
Hundreds of patients with advanced disease will be denied Abraxane, which extends life by two months when there are virtually no other options after experts decided the drug was not cost effective enough. (Source: the Mail online | Health)
Source: the Mail online | Health - December 30, 2014 Category: Consumer Health News Source Type: news

Specialised Therapeutics Australia To Increase Pancreatic Cancer Treatment Cost
Specialised Therapeutics Australia could not come to an agreement with the Australian government on the price of Abraxane, a drug for pancreatic cancer. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 28, 2014 Category: Pharmaceuticals Source Type: news

TGen Physician-in-Chief Dr. Daniel Von Hoff inducted today into Joshua Lederberg Society
(The Translational Genomics Research Institute) Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute, will be inducted today into the Joshua Lederberg Society for his work in developing the drug Abraxane for advanced pancreatic cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 13, 2014 Category: Biology Source Type: news

Drug offers new hope in pancreatic cancer battle: Treatment that can extend life by two months licensed for use in the UK
The drug, called Abraxane, is being hailed as the biggest advance in almost two decades against a disease that kills four in five sufferers within a year. (Source: the Mail online | Health)
Source: the Mail online | Health - February 6, 2014 Category: Consumer Health News Source Type: news

ABRAXANE® plus gemcitabine receives European Marketing Authorization for metastatic pancreatic cancerfor
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), has announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 15, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news

OncoMed starts Phase Ib study of combination therapy in pancreatic cancer patients
OncoMed Pharmaceuticals has initiated a multi-centre Phase Ib clinical trial of its first-in-class Wnt-pathway-targeting decoy receptor OMP-54F28 (Fzd8-Fc) with nab-paclitaxel (Abraxane) and gemcitabine in pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - January 14, 2014 Category: Pharmaceuticals Source Type: news

Celgene receives European approval for ABRAXANE plus gemcitabine combination therapy for pancreatic cancer treatment
Switzerland-based Celgene International has received approval from the European Commission (EC) for ABRAXANE plus gemcitabine combination therapy for first-line treatment of adult patients with metastatic pancreatic cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 9, 2014 Category: Pharmaceuticals Source Type: news

UCLA researcher highlights advances in nanotechnology's fight against cancer
As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.   A new research review co-authored by a UCLA professor provides one of the most comprehensive assessments to date of research on nanomedicine-based approaches to treating cancer and offers insight into how researchers can best position nanomedicine-base...
Source: UCLA Newsroom: Health Sciences - December 18, 2013 Category: Universities & Medical Training Source Type: news

Novel Agent Set for Unique Clinical Test in Inflammatory Breast Cancer
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center. The finding, published in a recent issue of the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy for advanced inflammatory breast cancer (IBC). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

OncoMed begins third Phase Ib combination therapy study of pancreatic cancer
OncoMed Pharmaceuticals has initiated a Phase Ib clinical trial of its Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2013 Category: Pharmaceuticals Source Type: news

Positive CHMP opinion for ABRAXANE®
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), has announced that the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 25, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news

Chemo Agents Equal in Treating Gastric Cancer (CME/CE)
(MedPage Today) -- Weekly paclitaxel (Abraxane) was as effective as biweekly irinotecan (Camptosar) as second-line therapy for advanced gastric cancer, researchers found. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 4, 2013 Category: Gastroenterology Source Type: news

UCLA faculty member's foundation gives $4 million to UC Global Health Institute
The Chan Soon-Shiong Family Foundation has donated $4 million to the University of California Global Health Institute to support new cross-campus and interdisciplinary education and research programs that aim to improve the health and well-being of vulnerable people and communities throughout California and across the globe.   The Los Angeles–based foundation was founded by Dr. Patrick Soon-Shiong, a UCLA faculty member, inventor and philanthropist, and his wife, Michele Chan, a television and film actress.   "Students are demanding a global education, and one mission of the Global Health Institute is ...
Source: UCLA Newsroom: Health Sciences - November 4, 2013 Category: Universities & Medical Training Source Type: news

Celgene profit tops Street view; raises 2013 forecast
(Reuters) - Celgene Corp on Thursday reported a slightly higher-than-expected third-quarter profit as sales of its flagship blood cancer drug Revlimid and of Abraxane for breast and lung cancer grew, and the company raised its 2013 earnings forecast. (Source: Reuters: Health)
Source: Reuters: Health - October 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Patients with advanced pancreatic cancer benefit from Abraxane (nab-paclitaxel)
By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published by The New England Journal of Medicine... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 18, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news

Nab-Paclitaxel Added to Gemcitabine Increases Survival in Metastatic Pancreatic Cancer (FREE)
By Joe Elia Patients with metastatic cancer of the pancreas showed better overall survival on a regimen of gemcitabine plus albumin-bound paclitaxel than with gemcitabine alone, according to a New England Journal … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 17, 2013 Category: Primary Care Source Type: news

Abraxane for the Treatment of Late-Stage Pancreatic Cancer
Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - September 15, 2013 Category: Pharmaceuticals Source Type: news

FDA approves pancreatic cancer drug Abraxane
US-based Celgene Corporation's chemotherapy drug Abraxane has received approval by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer, in combination with gemcitabine. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 9, 2013 Category: Pharmaceuticals Source Type: news

Abraxane Approved for Late-Stage Pancreatic Cancer
Title: Abraxane Approved for Late-Stage Pancreatic CancerCategory: Health NewsCreated: 9/6/2013 4:36:00 PMLast Editorial Review: 9/9/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 9, 2013 Category: Cancer & Oncology Source Type: news

FDA OKs Abraxane for Pancreatic Cancer
WASHINGTON (MedPage Today) -- The FDA has expanded the indications for protein-bound paclitaxel (Abraxane) to include treatment of late-stage pancreatic cancer. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 7, 2013 Category: Gastroenterology Source Type: news

F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer
The Food and Drug Administration has approved Abraxane, which in a clinical trial prolonged the lives of patients by a little less than two months on average.     (Source: NYT Health)
Source: NYT Health - September 6, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Pancreatic Cancer Clinical Trials JPMorgan Chase & Company JPM NYSE Drugs (Pharmaceuticals) Food and Drug Administration Celgene Corporation CELG NASDAQ Abraxis BioScience, Incorporated ABBI NASDAQ Abraxane (Drug) (Des) Source Type: news

FDA Approves Abraxane for Pancreatic CancerFDA Approves Abraxane for Pancreatic Cancer
Clinicians now have additional help for tough-to-treat metastatic disease. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Approval Based on MPACT Study of ABRAXANE in Combination with Gemcitabine Demonstrating a Clinically Meaningful Increase in Overall Survival First New Treatment Approved for Metastatic Adenocarcinoma of the Pancreas in Nearly 8 Years SUMMIT, N.J.--(H... Biopharmaceuticals, Oncology, FDACelgene, ABRAXANE, paclitaxel, Pancreatic Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 6, 2013 Category: Pharmaceuticals Source Type: news

FDA okays Celgene's Abraxane for pancreatic cancer
(Reuters) - U.S. regulators on Friday approved use of Celgene Corp's Abraxane to treat patients with pancreatic cancer that has spread to other parts of the body, citing a trial that showed the drug significantly prolonged survival. (Source: Reuters: Health)
Source: Reuters: Health - September 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news